ASLN

Stats

Summary

aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.

Market Cap: 5.08 Million

Primary Exchange: NASDAQ

Website: http://aslanpharma.com/zh/

Shares Outstanding: 7.6 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.2000598313589923

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1738 trading days

From: 2018-06-07 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor